Voyager Therapeutics, Inc.’s Post

Switzerland is undoubtedly a lucrative destination for biotech investment. Labiotech.eu's recent article highlights Switzerland's rising prominence as a global leader in biotechnology, supported by its breathtaking landscapes and exceptional cuisine. Swiss biotech companies are often at the forefront of developing cutting-edge treatments across healthcare, including oncology, immunotherapy and regenerative medicine. We’ve delved into some of the top biotech firms from the article’s list of 18, including Alentis Therapeutics, Endogena Therapeutics, Inc., and STALICLA, that are leading the charge in revolutionising healthcare. Swipe through to explore their ground-breaking innovations, and connect with Hobson Prior for further insights into the biotech industry and exciting career opportunities: https://www.hobsonprior.ch Read the full article here to find out who else made the list: https://lnkd.in/gnPbAhQ #SwissBiotech #Oncology #Immunotherapy #BiotechInnovation #Healthcare #Switzerland #LifeSciences

We are excited to connect with all of you at the Tumor Models Summit next week! We are especially looking forward to seeing you at our workshop led by our CEO, Eric Ibsen, titled “Best Practices and Technologies for Improving Animal Study Reproducibility,” on January 30th from 9 AM-12 PM. We will share some, pitfalls, success factors, practical approaches, and technological solutions to make animal studies more reproducible. #studylog #tumormodels #oncology

ICYMI: Check out the deep dive (25 slides!) report on 2023 #biotech Series A rounds from my BioCentury Inc. colleague Danielle Golovin, Ph.D. ✅ Access full PPT deck (subscribers only): https://lnkd.in/dP-j_fdW Not a subscriber? Send my colleague Matt Krebs a note to get a copy of the report. The report answers these questions: ➤ Who were the top VCs investing in Series As? ➤ What were the top disease areas for Series As? (Yes, oncology and neurology, but after that?) ➤ How many Series A biotechs were acquired or landed a deal with #pharma? ➤ What technologies saw the most Series As? ➤ How many Series A biotechs were preclinical vs. in the clinic? And much more... Check it out today. #biopharma #venturecapital #venturefunding

I am excited to announce the launch of Diagonal Therapeutics. We are advancing a ground-breaking approach to agonist antibody therapeutics. Our DIAGONAL platform has enabled the discovery of agonist antibodies to four different heteromeric receptor complexes. We have solved the longstanding challenge that has limited agonist antibody drug discovery by skillfully blending computational and experimental techniques - allowing us to move efficiently (8 months or less to agonist antibody discovery) - a timeframe previously unimaginable using historical methods. The rapid advancement of our lead programs for hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH) demonstrate the power of the DIAGONAL platform and breadth of opportunities yet to be solved using our approach. #innovation #antibodies #biotechnology #partnerships

Celebrating Six Years of Innovation at MAIA Biotechnology! Today we commemorate a significant milestone for MAIA as we celebrate six years of pioneering research and development. From humble beginnings in 2018, MAIA has since evolved into a dynamic organization with a robust pipeline of telomere-targeting therapies for cancer treatment. We've achieved numerous milestones, including establishing strategic partnerships, conducting successful clinical trials, and expanding our global reach. Here’s a recap of achievements in 2024 so far: • Exceptional measures of efficacy by lead drug THIO in Phase 2 clinical trial • Most recent data showed THIO’s strong outperformance against standard-of-care treatments in #NSCLC • 38% ORR in third-line NSCLC patients (THIO 180mg) vs. ~6% for currently available treatments in a similar population • 5.5 months median progression-free survival also in third-line NSCLC, more than double PFS of current chemotherapy treatments • Secured continued insider investment through independent board members’ participation in private placement equity financings • Funding of more than $12M year-to-date, including $7.4 million in Q2’24 Thanks to the brilliant minds of Dr. Vlad Vitoc, MD, MBA, Dr. Jerry Shay, and Dr. Sergei Gryaznov, and the unwavering dedication of our entire team, we've made remarkable strides. We would also like to thank our investors and partners for your continued support. As we look ahead, we remain committed to our mission. Here's to many more years of innovation and success! #CancerResearch #Biotech #Innovation

According to the World Health Organization, AI-powered drug discovery platforms have slashed the time and cost of bringing new cancer drugs to market by up to 50%! This remarkable advancement is paving the way for the development of more targeted and effective therapies. By harnessing the power of artificial intelligence, researchers can sift through vast amounts of data and identify promising drug candidates with unprecedented speed and accuracy. This accelerated drug discovery process allows for quicker translation of scientific discoveries into life-saving treatments for cancer patients. #AIinOncology #PrecisionMedicine #CancerResearch #DrugDiscovery #ArtificialIntelligence #MedicalInnovation #HealthTech #PersonalizedMedicine #InnovationInHealthcare #CancerTreatment #HealthcareAI #ClinicalTrials #DigitalHealth #Biotechnology #OncologyResearch

🧱 Builders w/ Tom Miller - Co-Founder & CEO @ Iambic Therapeutics Embark on a fascinating journey into the world of cutting-edge biotech innovation with CEO Tom Miller of Iambic Therapeutics on the BIOS Builders podcast. In this episode, discover firsthand insights into groundbreaking gene therapy treatments for rare diseases and the transformative impact of AI-driven drug discovery. Join us as we delve into the intricacies of precision medicine and explore the future of personalized healthcare. During the podcast, Tom Miller shares insights into pioneering therapies for neurological disorders, revealing their vision for patient impact & accelerated timelines with their platform, NeuralPLexer. Additionally, get an exclusive glimpse into the future of Iambic Therapeutics with Tom as he projects the company's trajectory to 2050 and beyond on BIOS Builders. Explore their expansion into new therapeutic areas and their utilization of AI for clinical success. Delve deeper into the future of AI in drug development with Tom Miller of Iambic Therapeutics, where he discusses technologies like physics-based AI and microfluidics shaping the next generation of therapies. Tune in: https://buff.ly/3y9wyRK #BiotechInnovation #PrecisionMedicine

Excited to announce the launch of Diagonal Therapeutics. We have rapidly discovered agonist antibody candidates against four complex targets, providing new paths to targeting the root cause of severe diseases. Our platform is agnostic and can work across any therapeutic areas. Our initial programs target two vasculopathies with high unmet need: Hereditary hemorrhagic telangiectasia (HHT): HHT is an orphan disease that affects more than 150,000 patients in the US and EU and for which there are no approved therapies. Pulmonary arterial hypertension (PAH): PAH is an orphan disease that results in high blood pressure that affects the arteries in the lungs and the right side of the heart. Our approach also capitalizes on the excellent properties of antibodies: superior potency and selectivity, tunable and sustained pharmacology, excellent developability, and low immunogenicity to develop optimal drug candidates for patients. #raredisase #orphandisease #antibodies #innovation

🧱 Builders w/ Tom Miller - Co-Founder & CEO @ Iambic Therapeutics Embark on a fascinating journey into the world of cutting-edge biotech innovation with CEO Tom Miller of Iambic Therapeutics on the BIOS Builders podcast. In this episode, discover firsthand insights into groundbreaking gene therapy treatments for rare diseases and the transformative impact of AI-driven drug discovery. Join us as we delve into the intricacies of precision medicine and explore the future of personalized healthcare. During the podcast, Tom Miller shares insights into pioneering therapies for neurological disorders, revealing their vision for patient impact & accelerated timelines with their platform, NeuralPLexer. Additionally, get an exclusive glimpse into the future of Iambic Therapeutics with Tom as he projects the company's trajectory to 2050 and beyond on BIOS Builders. Explore their expansion into new therapeutic areas and their utilization of AI for clinical success. Delve deeper into the future of AI in drug development with Tom Miller of Iambic Therapeutics, where he discusses technologies like physics-based AI and microfluidics shaping the next generation of therapies. Tune in: https://buff.ly/3y9wyRK #BiotechInnovation #PrecisionMedicine

[BLOG POST] Dive Deeper into the Future of Therapeutics! Get ready for the next part of our ground-breaking blog series - 'The Future is Non-Viral,' where we delve even further into the exciting realm of therapeutic advancements. In this sequel, we continue to explore the insights shared by Ken LeClair, Chair of RoslinCT’s Scientific Advisory Board, uncovering the transformative potential of non-viral vector alternatives. Discover how cutting-edge cellular reprogramming techniques are revolutionizing the field and learn about the latest advancements that are reshaping tomorrow's therapies. Read the blog post: https://lnkd.in/ehQxp_an #TherapeuticDelivery #SABPerspectives #Roslinsights